Skip to content
MARKETS / NASDAQ / XAIR
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Beyond Air, Inc. XAIR

10 fiscal years on record · USD · FY2025 reported · SEC filings only
$7.7M
▲ 107.3% YoY
$-33.2M
$-19.2M
In brief

What this company does

We are a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (“NO”) generators and delivery systems (the “LungFit® platform”) capable of generating NO from ambient air. The Company’s first device, LungFit® PH received premarket approval (“PMA”) from the FDA in June 2022. We were incorporated on April 24, 2015. On June 25, 2019, our name was changed to Beyond Air, Inc. from AIT Therapeutics, Inc. Invoicing and cash collection are managed by our Garden City, New York headquarters. As of March 31, 2026, we had 54 employees globally, all of whom were full-time employees.

Written from the business description in Beyond Air, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 26 June 2026. Every sentence was checked against that document before publication.

Growth
USD 7.7M
Revenue, FY2025 · full 10-year series below
Revenue $M Net income $M
FY2025 · Revenue 7.7 · Net income -33.2
4.0M-25.0M-50.0M2016201720182019202020212022202320242025
Compound annual growth
+54.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +54.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−447 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -378.2% · Net -447.1%
-2000%-4000%2016201720182019202020212022202320242025
ROE
FY2025 · ROE -337.4%
-100%-200%-300%2016201720182019202020212022202320242025

Each USD of equity lost 337 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -19.2
-25.0M-50.0M2016201720182019202020212022202320242025
Net buybacks $ Dividends $
FY2017 · Dividends — · Net buybacks 23801.0
8000160002017

Total assetsUSD 35.4M
EquityUSD 6.1M
CashUSD 6.7M
Current ratio3.80×

Equity funds 17% of total assets.

The 10-year record
10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016
Revenue $B0.00.00.0··0.00.00.0··
Operating income $B−0.0−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B······−0.0··0.0
Net income $B−0.0−0.0−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.1−0.0−0.0−0.0−0.00.0−0.0·
EPS, diluted $−4.01−13.77−1.82−1.86·−1.27−1.78−0.77−3.01−2.69
Dividend / sh $··········
Payout %··········
ROE %−337.4−241.4−191.4−100.9−83.7−94.2−180.3−235.5··
Shares out B0.010.000.050.030.030.020.020.010.010.00

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 43 reconciliationsAUDITED

Reconciled in 10 of 19 fiscal years. 52 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsMarch 31
SEC categorysmaller reporting company
Data on record since2016

Share this section

Download image